Efficacy and safety of BI 671800, an oral CRTH2 antagonist, as add on therapy in poorly controlled asthma patients prescribed an inhaled corticosteroid

I. Hall, M. Sarno, B. Disse, S. Atis, E. Beck, E. Bateman, H. Finnigan, C. Hallmann, A. Gupta, A. Fowler (Nottingham, Bracknell, United Kingdom; Ingelheim, Ruedersdorf, Biberach an der Riss, Germany; Mersin, Turkey; Cape Town, South Africa)

Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma
Session: Trials in asthma: asthma exacerbations and severe asthma
Session type: Poster Discussion
Number: 1792
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
I. Hall, M. Sarno, B. Disse, S. Atis, E. Beck, E. Bateman, H. Finnigan, C. Hallmann, A. Gupta, A. Fowler (Nottingham, Bracknell, United Kingdom; Ingelheim, Ruedersdorf, Biberach an der Riss, Germany; Mersin, Turkey; Cape Town, South Africa). Efficacy and safety of BI 671800, an oral CRTH2 antagonist, as add on therapy in poorly controlled asthma patients prescribed an inhaled corticosteroid. Eur Respir J 2012; 40: Suppl. 56, 1792

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
First line maintenance therapy for asthma: an observational study comparing inhaled corticosteroid monotherapy to combination inhaled corticosteroid/long acting beta agonist therapy in UK general practice
Source: Annual Congress 2007 - Traditional and novel approaches to assess and achieve asthma control
Year: 2007


Step-up of asthma therapy: an observational study comparing increased inhaled corticosteroid dosage to combination inhaled corticosteroid/long acting beta agonist therapy in UK general practice
Source: Annual Congress 2007 - Traditional and novel approaches to assess and achieve asthma control
Year: 2007


Efficacy and safety of BI 671800, an oral CRTH2 antagonist in controller naïve patients with poorly-controlled asthma
Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD
Year: 2012

The safety and tolerability of twice-daily oral doses of AZD5069, a novel CXCR2 antagonist, in patients with moderate-to-severe COPD
Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD
Year: 2012

Should guidelines be revised for add-on therapy in asthma? A 2 year randomized pragmatic equivalence trial of leukotriene antagonists (LTRAs) and long-acting beta agonists (LABAs) with inhaled corticosteroids (ICS) in primary care
Source: Annual Congress 2008 - Wider aspects of managing respiratory disease in primary care
Year: 2008


Efficacy and safety of as-needed corticosteroid plus fast or short-acting beta-agonists monotherapy in patients with mild asthma: a meta-analysis of randomised controlled trials.
Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma
Year: 2020

Impact of the combination therapy: inhaled corticosteroid and long-acting beta agonists in the prescription pattern of inhaled corticosteroids
Source: Annual Congress 2007 - Respiratory issues in primary care
Year: 2007


Long-acting β2-agonists provide greater benefit compared to leukotriene antagonists when added to inhaled corticosteroids in patients with symptomatic asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 310s
Year: 2004

The impact of tiotropium on mortality when added to inhaled corticosteroids and long-acting beta agonist therapy in COPD
Source: Annual Congress 2011 - Bronchodilators in asthma and COPD
Year: 2011

Efficacy and safety of high-dose inhaled corticosteroids therapy in children with asthma
Source: Annual Congress 2010 - Allergy and risk factors in paediatrics
Year: 2010


Efficacy and safety of AZD3199, an inhaled ultra long-acting β2-agonist, in patients with COPD
Source: Annual Congress 2011 - Bronchodilators in asthma and COPD
Year: 2011

Tolerability and efficacy of inhaled AZD4818, a CCR1 antagonist, in moderate to severe COPD patients
Source: Annual Congress 2009 - New drugs for airways disease
Year: 2009

Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD
Source: Eur Respir J 2003; 22: Suppl. 45, 50s
Year: 2003

Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness
Source: Eur Respir J 2006; 27: 1144-1151
Year: 2006



One-year pulmonary safety and efficacy of inhaled insulin as adjunctive therapy in type 2 diabetes patients poorly controlled on oral agent monotherapy
Source: Eur Respir J 2004; 24: Suppl. 48, 618s
Year: 2004

24-h duration of the novel LABA vilanterol trifenatate in asthma patients treated with inhaled corticosteroids},
Source: Eur Respir J 2012; 40: 570-579
Year: 2012



Efficacy of indacaterol in COPD is maintained irrespective of inhaled corticosteroid (ICS) use
Source: Annual Congress 2011 - Bronchodilators in asthma and COPD
Year: 2011


Safety of formoterol reliever therapy compared with terbutaline in asthmatic children taking anti-inflammatory therapy
Source: Eur Respir J 2002; 20: Suppl. 38, 431s
Year: 2002

Real-life use and impact of inhaled steroids (ICS) and leukotriene receptor antagonists (LTRA) monotherapy in children with asthma
Source: Annual Congress 2010 - Paediatric asthma treatment and monitoring
Year: 2010

Efficacy of long-term formoterol therapy vs as-needed salbutamol use in patients with moderate asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 426s
Year: 2001